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1. Introduction 
Loss of olfactory function starts at 60 years and become significantly worse after 70. In many 
cases olfactory disorders may be a consequence of a disease. Different types of olfactory 
deficit may be revealed by smell evaluation. Anosmia is defined as inability to perceive all 
odors (total) or some odors (partial).  Hyposmia or microsmia is a decreased sensitivity to 
odors. Dysosmia is a distorted smell percpeption. Olfactory agnosia is defined as failure to 
identify odors in presence of normal detection and discrimination. Olfactory allucinations 
are named phantosmias. 
Many common diseases may compromise the sense of smell, permanently or temporaneally. 
The range of diseases causing olfactory disorders varies from the common cold to 
neurodegenerative diseases. Most common causes of olfactory loss are local nasal diseases 
(allergic rhinitis, nasal polyposis, sinus disease), head trauma, viral and bacterial infections 
of upper airways. Some neurodegenerative diseases like Alzheimer's disease (AD) and 
various forms of Parkinson’s disease (PD) are accompanied, even from their earliest stages, 
by olfactory disorders.  
Dementia is defined by the American Academy of Neurology as a progressive and 
permanent decline in cognitive function and affects nearly 15% of people who live up to 65 
years and 35% of those who reach the age of 85. The Alzheimer's Disease International (ADI) 
in Alzheimer World Report published in 2010 provides that an aging population with 
dementia - the most common form is AD which is currently estimated to affect 35,6 million 
of people - will nearly double in 20 years to reach 66 million in 2030 with a higher 
concentration in poor countries leading to enormous social costs.  
The research on AD is now oriented to an early diagnosis which is essential before the 
development of the irreversible and typical changes due to AD. In AD patients, a reduced 
capacity for olfactory detection, discrimination and identification is usually found and 
confirmed by several studies (Mesholam et al., 1998; Hawkes, 2003; Kovacs, 2004; Albers et 
al., 2006; Westervelt et al., 2007).  
In this chapter  we present a review on the predictive role of hyposmia in the early diagnosis 
of AD patients. 
2. Central mechanisms of smell 
Humans can detect more then 10.000 different odorants (Ressler KJ et al, 1994). 
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Odorants may be perceived through sniffing (ortonasal olfaction) and through the mouth 
(retronasal olfaction) (Heillmann S & Hummel T, 2004). The anatomical area covered by 
olfactory neuroepithelium is estimated between 100-400 mm2 (Moran DT  et al, 1982).  
The human olfactory neuroepithelium is localized in the superior turbinate, in the dorsal 
areas of the nasal vault and in the superior part of the nasal septum. Olfactory mucosa is 
composed of olfactory sensory neurons (OSNs), supporting cells, basal cells and Bowman’s 
glands.  
The OSNs are bipolar cells with a dendrite that ends in a knob with 10-25 projecting cilia.  
These cilia are covered by a layer of mucus which extends over the neuroepithelium and 
represent the site of sensory transduction. The cilia contain G-protein-linked receptors that 
bind to the odour molecules (Jones D & Reed RR, 1989): the expression of these receptors is 
still unclear.  
These receptors are proteins encoded by a family of 1,000 genes in the mammals (Buck L & 
Axel R, 1991) while in the humans 60% of OR genes appear to be pseudogenes (Sosinsky A 
et al, 2000). The G-protein activates an adenylyl cyclase that converts ATP into the second 
messenger cyclic adenosine 3’ monophosphate (cAMP) which is the major messenger for 
olfactory signaling.  
The cAMP opens a cyclic nucleotide-gated (CNG) channel. Cations (Na+ and Ca2+) entering 
through the CNG channels cause a membrane depolarization and generate an action 
potential which is propagated along the olfactory axon. The olfactory axon crosses the 
lamina propria and became an unmyelinated axon that penetrates the foramina of the 
cribriform plate and synapses in the glomerulus of the olfactory bulb where signals are 
integrated. In the glomeruli, the axons of the olfactory sensory neurons form synapses with 
the dendrites of the mitral and the tufted cells (second-order of neurons). The axons 
originated in the mitral and tufted cells leave the olfactory bulb and project to the olfactory 
tract, to the anterior olfactory nucleus, to the piriform lobe (prepiriform cortex, 
periamygdaloid cortex and entorhinal cortex) and to the limbic system (amygdala and 
hippocampus).  
The prepiriform cortex and the periamygdaloid cortex represent the primary olfactory 
cortex while the entorhinal cortex, which represents the secondary olfactory cortex, receives 
olfactory fibres from the primary olfactory cortex (Graph 1). 
When medication molecules come in contact with this specialized olfactory mucosa they are 
rapidly transported directly into the brain and achieved cerebrospinal fluid levels (faster 
than if the drug is given intravenously).  
This concept of molecules transfer from the nose to the brain is referred to the so called 
nose-brain pathway and has implications when centrally acting medications such as 
sedatives, anti-seizure drugs and opiates are delivered nasally (Hussain AA, 1989; Dale O et 
al., 2002; Westin et al, 2006).  
In this way the absorptive surface is not the intestinal mucosa so the drug is not subjected to 
hepatic metabolism and lead to early effects. Recently, Dale O (Dale O, 2010) indicated 
Intranasal fentanyl spray (INFS) as an effective treatment of breakthrough cancer pain; this 
formulation has been investigated as a new and convenient route of administration that may 
offer a rapid onset and short duration of analgesic effect. 
Many studies based on the functional imaging in humans, point to the role of the piriform 
cortex in odor classification and differentiation (Li et al. 2006; Howard et al. 2009).  
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Graph 1. Central olfactory pathways of the olfactory system 
The role of temporal lobe structures in olfactory memory was investigated (Dade LA et al., 
2002) by the convergent approach of examination of odour learning and memory in patients 
who had undergone resection from a temporal lobe (including olfactory regions) for the 
treatment of intractable epilepsy, as well as studying these aspects in the healthy brain, 
through the use of the PET.  
Some studies have also examined olfactory memory in patients with epilepsy before and after 
surgical intervention in different brain regions, and only subjects with resection within 
temporal lobe and orbitofrontal regions have shown impairments (West SE& Doty RL, 1995 ).  
The piriform lobe may have an active role not only in odour perception but also in odour 
memory processing without hemispheric superiority among patients with resection from 
the left or right temporal lobe regions (Dade LA et al. 2002). 
2.1 Diagnostic approaches for detecting olfactory disorders 
An accurate evaluation starts with an history to establish the type of olfactory disorder 
(hyposmia, anosmia), the onset (rapid, slow) and progression, the presence of concomitant 
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nasal diseases, previous trauma and neurological symptoms, occupational exposure, 
medications, alcohol and tobacco consumption. A nasal examination is necessary to exclude 
signs of nasal diseases. 
Sophisticated investigations like computed olfactometry and electrophysiological tests are 
available. Computed olfactometry  provides the precision of the stimulus presentation and 
data collection but it is expensive and it requires a long time for administration. That is why 
it is restricted to specialized centers. The electrophysiological tests such as the odor event-
related potentials evaluate the integrated electrical activity at the surface of the scalp but 
require a complex stimulus presentation and recording equipment. 
For this reason in the last 20 years many practical and reliable psychophysical tests of 
olfactory function have been developed and largely diffused (Table 1). 
 
Olfactory tests Olfactory function tested 
University of Pennsylvania Smell Identification 
Test (UPSIT) 
Identification 
Sniffin’ Sticks (SS) Identification, discrimination, threshold 
Cross-Cultural Smell Identification Test (CC-
SIT) 
Identification 
Quick Smell Identification Test (Q-SIT) Identification 
Odorant confusion matrix Identification 
Biolfa olfactory test Identification 
Brief Smell Identification Test (B-SIT) Identification 
Smell diskettes test Identification 
Smell Threshold Test (STT) Threshold 
T&T Olfactometer Threshold 
Olfactory Perception Threshold Test (OPTT) Threshold 
Sniff Magnitude test Psycolfaction 
12-item Odour Memory Test Odorant Memory, discrimination 
Table 1. Olfactory tests and respective olfactory function tested 
Most of modern olfactory tests are brief and easy to use. Unilateral test with occlusion of the 
nostril controlateral to the tested side is preferred to evidence a monolateral anosmia which 
can be undervalued with a bilateral test. 
In regard to cross-cultural differences in olfactory assessment, several olfactory tests have 
been proposed over the years to study smell function and its quantifiable parameters such 
as threshold, identification, discrimination and memory. 
The odor threshold test measures the lowest concentration of a stimulus that can be discerned. 
Modern olfactory tests evaluate the detection threshold which is the lowest odorant 
concentration where such a presence is detected but not recognized (Stevens JC et al., 1988; 
Kobal G et al., 2000). 
The odor discrimination test evaluates the ability to differentiate between odorants and 
requires the subject to decide whether two stimuli are similar or different (Kobal G et al., 
2000)without requiring the identification. 
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The odor identification test evaluates the subject’s ability to identify an odorant at the supra-
threshold level. The multiple-choice identification test is the most sensitive and specific 
procedure to assess identification. In this type of test the subject identifies the stimulus from 
a list of odor names (Doty RL et al., 1984; Cain WS et al., 1988; Simmen G et al., 1999; Kobal 
G et al., 2000). 
To evaluate odor memory, the subject is required to smell an inspection odorant and to select 
the same odorant from a set of alternatives choices after a delay period of 10, 30 or 60 
seconds (Campbell IM et al., 1972). 
Several threshold tests are available like the Smell Threshold Test (Doty RL, 2000), the odor 
threshold test of Sniffin’ Sticks (Hummel T et al, 1997) and the T&T olfactometer (Toyota B 
et al. 1978).  
In most cases a marked variability in threshold values depends on the techniques of 
stimulus presentation, interstimulus time, method of stimulus dilution, number of trials 
presented, confusion of the subject between detection and recognition of the stimulus.  
Currently the most widely identification  tests used  are  screening tests, as the Brief Smell 
Identification test (Doty et al., 1995) (B-SIT) and the Sniffin 'Sticks Screening Test (Kobal G et 
al.,1996;Hummel et al., 2001) (SSST) (Burghart GmbH, Wedel, Germany) and complete tests 
as the University of Pennsylvania Smell Identification Test (Doty et al., 1984) (UPSIT) 
(Sensonics, Inc., Haddon Heights, New Jersey, USA) and the Sniffin 'Sticks Extended Test 
(Hummel et al., 1997) (SSET). Therefore it is recommended a full assessment of respiratory 
function with naso-pharyngeal nasal endoscopy and rhinomanometry. After examination, 
further diagnostic investigations such as citology, CT or MRI of the nose and paranasal 
sinuses, may be prescribed to verify an insufficient ventilation in the presence of nasal or 
sinus diseases which make the olfactory test less reliable by substantially reducing its 
specificity and sensitivity.  
2.1.1 Sniffin’ Sticks 
The SSST is a test of olfactory identification by the administration of 12 odors  presented in 
felt-tip pens (sticks) (Hummel et al., 2001). Few hours prior to the test food intake is limited 
only to water. The subject is asked to identify among 4 written names of  different odours 
the one smelled on a specific single odour stick. Based on the final score, adjusted per age 
and sex, subjects are classified in three categories: normosmic (>12) hyposmic (< 10) and 
anosmic (< 6). As opposed to neuropsychological tests the smell test is not influenced by the 
level of schooling. Our experience in administering the SSS test also showed that almost all 
of the test odors are familiar to Italian subjects except for cloves. In fact 23 of 102 normal 
subjects tested by us with the SSS test didn’t know the cloves but they correctly identified it 
with the aid of the four possible answers.  
The SSET provides for the assessment of olfactory identification, discrimination and 
threshold (Kobal et al., 2000).  
The olfactory identification is evaluated with 16 odors which are presented to the patient 
using a 4-alternative forced-choice task with presentation of a list of 4 descriptors for each 
pen (normal value: ≥12 correct identifications).  
The olfactory threshold is achieved by presenting the patient 16 triplets of sticks: only one of 
three sticks contains a smell, not the other two and the patient must recognize that stick 
smells unlike the other 2. The 16 odors presented to the patients for the threshold, are 16 
dilutions of n-butanol. Odor threshold was represented by the mean of the last 4 out of 7 
staircase reversals (normal values: >6 for men, >6.5 for women).  
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For the assessment of olfactory discrimination 16 triplets of odors are presented to the 
patient. In each triplet two sticks have the same smell and a stick has a different smell: the 
patient must recognize the stick with different smell (normal value: ≥11 correct 
discriminations).  The execution time of SSET varies from 25 to 45 minutes.  
The sum of the three scores in the evaluation of threshold, discrimination and identification 
gives us the total score (TDI score) and classifies the subject as normosmic (> 30.5), 
hyposmic (≤ 30.5) or anosmic (≤ 15.5)(Hummel et al., 2007). 
The SS test is largely used to evaluate olfactory dysfunction in neurodegenerative disorders 
like Parkinson’s disease (Daum RF 2000), Alzheimer and MCI (Peters JM et al., 2003). 
2.1.2 UPSIT 
The UPSIT is a scratch and sniff test used in North America since 1984 (Doty et al., 1984). 
The UPSIT is a multiple-forced-choice odor identification test available in 11 languages. For 
each odorant there are four alternative responses and the subject is required to choose one of 
these even if no smell is perceived. It requires 10 to 15 minutes to be administered. This test 
consists of 40 odorants at the supra-threshold level embedded in microencapsulated crystals 
in four booklets, each containing 10 odorants. Every odorant is located on brown strip that is 
“scratched” with a pencil. The UPSIT detects most olfactory disorders (anosmia, severe 
microsmia, moderate microsmia, mild microsmia) and also identifies malingerers on the 
basis of improbable responses. Malingerers avoid the correct response more often than 
expected on the basis of the chance (zero score detects a malingerer). The test-retest 
reliability is high (r=0.92) (Doty RL et al., 1989). Normative data for the UPSIT include a 
score on a scale of 0-40 to evaluate olfactory dysfunction and percentile ranks for men and 
women across the entire age span.  
Some odorants of the UPSIT as root beer, skunk, fruit punch and pumpkin pie may be 
unfamiliar to patients outside of the USA. Although the UPSIT is a self-administered test, 
we underline the great importance of a ENT evaluation before each test administration 
because many pathologies involving nose and paranasal sinuses can interfere with the 
mechanical transport of the odorants to the olfactory areas with the consequent test failure. 
The 40-item UPSIT has been used to test olfactory dysfunctions in many  neurodegenerative 
disorders like AD (Doty RL et al., 1987; Hawkes C. 2003), MCI (Devanand  DP et al., 2000, 
Wang QS et al., 2002), Parkinsonism (Hawkes C. 2003), multiple sclerosis (Doty RL et al., 
1999). 
2.2 General diseases causing olfactory disorders 
Few studies have investigated the real prevalence of olfactory disorders in the population 
(Deems DA et al., 1991). According to a recent study the prevalence of measured olfactory 
impairment is 24.5% overall, but among elderly people it can be high as 70% (Murphy C et 
al., 2002). Disorders of the sense of smell are caused by conditions that interfere with the 
access of the odorant to the olfactory neuroephytelium (transport loss), injure the receptor 
region (sensory loss), or damage the central olfactory pathways (neural loss). Smell 
disorders may be typically intermittent or permanent. When the smell disorder is 
intermittent there are usually some conditions that interfere with the access of the odorant to 
the olfactory neuroephytelium and in these cases we suppose a transport loss. Most frequent 
causes of transport loss are nasal diseases and polyposis. The onset of hyposmia is more 
gradual and intermittent, the recovery is possible with an adequate medical or surgical 
treatment. Conversely, a permanent olfactory dysfunction may be secondary to an injure of 
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the receptor region when there is a sensory loss (like in prior upper respiratory infections 
and toxic exposure) or secondary to a damage of the central olfactory pathways in case of 
neural loss (like in head trauma). A temporary hyposmia often occurs with a prior upper 
respiratory infection but in a small percentage of cases olfaction never returns. Temporary 
or permanent hyposmia due to toxic exposure can occur through modification of 
neurotransmitter levels or anatomical damage to the olfactory receptor. Even a minor head 
trauma can produce a total anosmia and recovery occurs in fewer than 10 %, most occurring 
several months. Olfactory impairment is a common occurrence in aging and may be an early 
signal of neurodegenerative disease. Olfactory loss caused by aging and diseases effects 
both quality of life and personal safety. Aging as well as prior upper respiratory infections, 
head trauma (approximately 5-10% of adult patients with head trauma report olfactory loss 
to be in anosmic range) and nasal and/or sinus diseases lead to smell dysfunction but 
frequently the cause of the olfactory loss remains unknown (idiopathic smell dysfunction). 
Disorders of olfactory function have been also associated with the exposure to toxic 
chemicals, tobacco smoking, endocrine disorders (hypothyroidism, diabetes, Kallmann’s 
syndrome, Cushing syndrome) and neurodegenerative diseases (Table 2). Among these, 
Alzheimer’s disease (AD) is one of the earliest to be reported and studied in detail. 
 
Nasal/sinus diseases 
Head trauma 
Prior upper respiratory infections (viral, bacterial) 
Idiopathic 
Toxic exposure (drugs, airbone compounds like metals, dusts, ecc.) 
Neurodegenerative diseases 
Congenital 
Endocrine disorders (hypothyroidism, diabetes, Kallmann’s syndrome, Cushing 
syndrome) 
Tumors (olfactory groove meningioma, temporal lobe glioma, nasopharyngeal carcinoma) 
Table 2. Main disorders associated with smell dysfunction 
2.3 Clinical and pathological features of hyposmia in different CNS diseases 
Hyposmia is one of the markers of a future cognitive decline but it is not specific for AD 
because it can also precede other neurological diseases, like PD and multiple sclerosis (Table 
3). 
Although genetic predisposition in undoubtedly relevant in AD (older people with Down 
syndrome inevitably developed AD) environmental agents cannot be ignored (Table 4). 
Particular attention should be paid to recent theories suggesting the olfactory 
neuroepithelium as a major point of invasion by external pathogens such as viruses, ionized 
metals (cadmium, gold, manganese) and nanoparticles to the central nervous system 
(Charles et al., 1995; Itzhaki et al., 2004; Doty, 2008).  
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Alzheimer’s disease Mild Cognitive Impairment 
Idiopathic Parkinson’s disease Guam Parkinson’s disease-dementia complex 
Dementia with Lewy bodies Down syndrome 
Amyotrophic lateral sclerosis Huntington’s disease 
Multiple sclerosis Motor neuron disease 
Pallidopontonigral degeneration Korsakoff’s psychosis 
Multiple system atrophy (type-P) Friedreich’s ataxia 
Table 3. Neurodegenerative diseases associated with olfactory dysfunction  
 
Viruses 
Toxic metals (cadmium, iron, manganese) 
Air pollutants 
Herbicides (rotenone) 
Defoliants 
Table 4. Possible environmental agents implicated in the “olfactory vector hypothesis” 
The “olfactory vector hypothesis" suggests that certain viruses could be transported directly 
from the olfactory epithelium to the olfactory bulb and the central regions of the limbic 
system, without intermediate synapses, not causing damage to the epithelium, but only 
using this route to reach the brain (Youngentoub et al., 2001).  
The “olfactory vector hypothesis” may explain how some neurodegenerative diseases like 
AD and PD may be caused by external patogenes that damage the olfactory system and 
enter the brain through the nose possibly in accordance with genetically determined 
substrates (Youngentoub et al., 2001).  
Different brain cells may be infected by viruses in the presence or absence of certain specific 
receptors to which the virus would bind. However the entry of a pathogen through the nose 
seems more feasible as a cause of PD than AD. 
2.3.1 Alzheimer’s disease 
In the preclinical phase which can precede over decades the disease, the presence of typical 
lesions of AD as amyloid plaques and neurofibrillary tangles have been demonstrated, even 
at the level of brain areas involved in olfactory function. Until few years ago it was thought 
that the beta-amyloid, the first 42 aminoacids of the amyloid precursor protein (APP), was 
just an inactive storage without biological activity. Recent researches have shown that the 
Aǃ-42 provides cellular cascades and it’s an initiator of the degeneration of neurons. The 
hyperphosphorylation of tau protein from which neurofibrillary tangles originate would be 
determined by the action of Aǃ42. Autoptic studies conducted in the olfactory 
neuroepithelium in the past proposed the hypotesis that the diagnosis of AD would be 
confirmed by the finding of typical lesions at this periferic level (Lovell et al., 1982; Talamo 
et al., 1989; Arnold et al., 2010). However, following studies showed that these changes were 
not specific for AD because they where similar to those found in other neurodegenerative 
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diseases and in control elderly subjects (Trojanowski et al., 1991; Kishikawa et al., 1994; 
Smutzer et al., 2003). The presence of amyloid plaques and neurofibrillary tangles has been 
widely described in all layers of the olfactory bulb and in the central olfactory pathway of 
patients with AD (Kovacs et al., 2001) with a significant association between the peripheral 
olfactory and cortical degenerative changes (Christen-Zaech S et al., 2003). However it is not 
yet determined whether the olfactory involvement first appears at peripheral levels, in the 
olfactory bulb or in the temporal cortex. 
There is a strict relationship between the loss of cells in the anterior olfactory nucleus, the 
development of anosmia, the extent of neurofibrillary degeneration and the severity of AD. 
It has long been known that the typical lesions of AD are early and selectively localized in 
rhinencephalon. This is not surprising when one considers that the rhinencephalon plays a 
key role in all processes of memory and that the first symptom in AD, the most important 
and included in all diagnostic systems as deemed necessary, is the early deficit of memory.  
Some authors point out in many patients with AD the presence of early anosmia with 
slowly progressive deterioration of cognitive disorder. According to some authors, the 
olfactory deficit in AD could be based on a genetic predisposition. The allele ε4 of 
apolipoprotein E gene is a known genetic marker of hereditary AD with a low prevalence 
and it is the subject of ongoing researches. Schiffman  (Schiffman SS et al, 2002) found that 
at-risk relatives of AD patients had higher detection thresholds and decreased odor memory 
than control subjects with an ApoE-4 status not associated with at-risk status. Conversely 
Graves (Graves et al., 1999) showed an increased risk of cognitive decline in patients with 
olfactory deficit and allele ε4, greater in males but with a trend also evident in females.  
The transentorhinal area  is  early impaired in AD and it would be the point of passage of 
the sensory cortical afferents to the hippocampus, followed by the involvement of the 
anterior parahippocampal cortex or the entorhinal area (Braak&Braak, 1998).  
In general terms, therefore, the entorhinal cortex receives a constant flow of informations 
from cognitive and sensory associative areas, that move towards the hippocampus to 
recover in a consolidated form. These informations are transmitted to the associative areas 
where they are encoded in the form of memory traces.  
In contrast with the hypothesis of early involvement of the transentorhinal area, Kovacs 
(Kovacs, 2001) argues that  neurofibrillary tangles are present in the anterior olfactory 
nucleus prior to the first changes observed in the entorhinal cortex.  
The primary olfactory cortex would also be less severely affected than medial orbitofrontal 
cortex (associative area) and there would be a correlation between the pathology of the 
olfactory bulb and some areas not involved in olfactory processes. 
2.3.2 Parkinson’s disease 
PD is a progressive neurodegenerative disease characterized by a loss of dopaminergic 
neurons in the substantia nigra. In the majority of cases it’s clinically diagnosed as 
idiopathic Parkinson’s disease (IPD). In the IPD the impairment of smell has been well 
documented in the early stages with the use of psychophysical tests (Doty et al., 1992; Daum 
et al., 2000, Muller et al., 2002; Ponsen MM et al., 2004; Haehner et al., 2007) and olfactory 
evoked response (Barz et al., 1997).  
Olfactory dysfunction is a non-motor symptom of PD which includes deficits in odor 
detection, discrimination and identification without any relationship with the duration or 
severity of parkinsonism and with the nigrostriatal dopamine depletion.  
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As confirmed by autoptical studies (Beach TG et al., 2009) the presence of ǂ-synucleinopathy 
in the olfactory bulb predicts, with greater than 90% sensitivity and specificity, the existence 
of neuropathologically confirmed PD.   
Recent findings support the association between anosmia and autonomic failure, like 
orthostatic hypotension, in sporadic PD so they might provide biomarkers of the 
pathogenetic process. (Kaufmann H et al., 2004; Goldstein D et al., 2010).  
Once IPD has become clinically manifest, olfaction appears to be already severely 
compromised, which is in line with the absence of longitudinal changes of olfactory function 
during IPD progression (Herting et al. 2008).  
In a recent study (Wattendorf E et al., 2009) gray matter atrophy was investigated using  
morphometric analysis of magnetic resonance images voxel-based morphometry (VBM) and 
it was related to psychophysically measured scores of olfactory function in early PD 
patients, moderately advanced PD patients  and age-matched healthy controls. Cortical 
atrophy in olfactory-related brain regions (mainly in the right piriform cortex in early PD 
patients and in the right amygdala in moderately advanced  PD patients) was shown in PD 
patients, but not in controls,  and it was specifically correlated with the olfactory 
dysfunction.  
A selective hyposmia in PD patients  correlated with hippocampal dopamine innervation as 
shown by DAT (dopamin transporter) PET binding was also demonstrated (Bohnen NI et 
al., 2008). These findings support the hypothesis of  selective deficits in odor identification  
correlating  with dopaminergic activity in the hippocampus, an area related to cognitive and 
memory processing.  
Dopamine replacement therapy, does not improve olfaction in PD, suggesting that 
hyposmia cannot be explained by dopamine deficiency alone (Doty RL et al.,1992). 
2.3.3 Multiple sclerosis  
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. In  MS 
(Doty et al., 1999) the olfactory abilities decline progressively over the course of the disorder. 
The presence of olfactory dysfunction in MS is confirmed by studies with UPSIT and 
olfactory evoked potentials (Hawkes CH et al., 1997) and with Sniffin’ Sticks (Fleiner F et al., 
2010). An important role could be entrusted to the association of olfactometric and 
neuropsychological measurements with imaging.  
2.3.4 Epilepsy 
The presence of olfactory deficits is also well known in epilepsy. Chen (Chen C et al.2003) in 
a study on  patients who underwent temporal lobectomy for medically intractable temporal 
lobe epilepsy (TLE) found olfactory auras in 12 (5.5%) patients. The conclusion of this study 
is that the mesial temporal sclerosis is the most common aetiology rather than tumors and 
that the mesial temporal structures, especially the amygdala, may play an important role in 
the genesis of olfactory auras. 
2.4 The role of olfactory test in Alzheimer's disease 
The olfactory identification tests are considered more sensitive and specific in distinguishing 
patients with AD from control subjects. Although it is not possible to determine how early 
the olfactory deficit appears in the course of AD, it is well established that its presence is an 
early and consistent element before the clinical diagnosis (Devanand et al., 2000; Royall et 
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al., 2002; Swan et al., 2002; Wilson et al., 2009). Some studies highlighted the increase in 
olfactory threshold in AD subjects rather than in the control group (Nordin et al., 1997) 
while other studies showed that the olfactory identification is compromised earlier than the 
perception.  
Anosmia, alongside at least one allele of Apo-E 4 may be associated with a risk five times 
higher to develop a subsequent cognitive decline (Graves et al., 1999). Wilson et al. (Wilson 
et al., 2007a) in a recent study showed a deficit of olfactory identification inversely related to 
AD (in particular with NFT in the entorhinal cortex and hippocampus) in elderly patients. 
The autopsy outcomes suggested that in elderly the olfactory identification deficit is partly 
due to the accumulation of NFT in the primary olfactory cortex.  
Hyposmia can predict the next start of mild cognitive impairment (MCI) in patients with a 
not yet measurable cognitive impairment (Wilson et al., 2007b) and an increased risk of AD 
was demonstrated in MCI patients with hyposmia associated with unawareness of the 
olfactory deficit (Devanand et al., 2000). Conversely Bahar-Fucks et al. suggest that 
unawareness of olfactory deficit does not improve the identification of patients with MCI 
progressing to AD (Bahar-Fuchs et al., 2011).  
Hyposmia incurs with a latency of less than 10 years since the beginning of clinical 
manifestations of the disease in patients with AD and autosomal dominant mutation of the 
presenilin-1(Nee et al., 2001).  Another explanation could be that the olfactory deficit is 
predictive only of sporadic forms of AD.  
In a recent study (Luzzi et al., 2007) the smell was measured in patients with mild semantic 
dementia, with frontotemporal dementia,  with corticobasal degeneration and  with mild 
AD. As expected, patients with AD showed lower scores in the discrimination, 
denomination and visual recognition. Patients with semantic dementia showed a normal 
discrimination but a marked reduction in denomination and olfactory agnosia. In patients 
with frontotemporal dementia and corticobasal degeneration there was a slight deficit of 
naming and discrimination.  
Compared to the olfactory tests the role of olfactory event-related potentials (OERPs) is 
considered useful in the diagnosis of AD (Morgan&Murphy, 2002).  
The results of olfactory tests are supported by functional imaging techniques (CT, MRI, PET) 
which show a reduced activation of the central olfactory structures (Wang et al., 2010), 
mainly on the right side (Kareken et al., 2001) and an atrophy of hippocampus (Jack et al., 
1992;Yousem et al., 2001) and olfactory bulb (Thomann et al., 2009).  
Murphy et al. (Murphy et al., 2003) studied olfactory function (odor threshold and odor 
identification) and volumetric MRI measures of mesial temporal areas (hippocampus, the 
parahippocampal gyrus and the amygdala) in  patients with probable AD. They found 
strong relationships between mesial temporal lobe volumes and olfactory functional 
measures, particularly between the left hippocampal volume and the performance on the 
odor identification task so they concluded a left-hemisphere prevalence for verbally 
mediated olfactory tasks. 
2.5 The role of olfactory test in Mild Cognitive Impairment 
In a recent study we highlighted the role of olfactory test in early diagnosis of dementia 
(Fusetti et al, 2010). 
The early identification of those patients which can develop a dementia before its clinical 
appearance has become a priority since they could benefit from therapeutic and preventive 
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options. For this reason in our researches we selected patients with Mild Cognitive 
Impairment (MCI). 
The term MCI defines a transient condition that occurs along the progression from normal 
aging to dementia and comprises a broad clinical spectrum of pre-dementia stages. Standard 
MCI diagnostic criteria are the following:  
1. subjective symptoms of memory loss 
2. pathologic performance in mnemonic testing in relation to age and level of schooling  
3. normal activities of daily living  
4. normal cognitive functions  
5. absence of dementia  
6. lack of other diseases which impair or may alter memory (Petersen et al., 2001). 
The discriminant role of the olfactory test was determined by the outcomes of a study on a 
group of patients with amnesic Mild Cognitive Impairment (aMCI) which is the category 
with the higher risk of conversion in AD (Peters et al., 2003). aMCI progresses to AD with a 
prevalence of 15% annually and they are identified clinically with neuropsychologic testing 
to determine isolated memory loss. 
In our study 29 patients diagnosed with aMCI were selected and reassessed at 18 months 
(T1) after the first visit (T0).  Exclusion criteria were considered neuropsychiatric disorders 
different from aMCI (Parkinson’s disease, schizophrenia, multiple sclerosis and depression), 
head trauma (with loss of consciousness greater than 15 minutes), maxillofacial surgery,  
rhinosinusitis, nasal polyposis, chronic obstructive pulmonary disease, asthma, active 
hepatitis, cirrhosis, chronic renal failure, vitamin B12 deficiency, alcohol and drug abuse, 
cerebral vascular accidents, insulin dependent diabetes mellitus, hypothyroidism and 
Cushing syndrome.  
The patients underwent an assessment by the SSST and the SSET and a neuropsychological 
evaluation using the Mini Mental State Examination (MMSE) and the Mental Deterioration 
Battery (MDB).  
The MMSE is a quick, simple and reliable screening test used to explore cognitive functions 
and to evaluate disease progression. However its applicability in differential diagnosis 
shows limitations as well, due to the low reliability in individualizing specific profiles of 
cognitive deficit. The MMSE requires 5-10 minutes and it provides a score between 0 and 30 
points adjusted according to the age and years of education in the Italian population. The 
MMSE score >24 was used as cut-off to distinguish between MCI and early dementia. 
The MDB discriminates with a high degree of accuracy AD patients from normal aging 
subjects and it provides qualitative informations on the cognitive deficit. The MDB is a 
battery including seven tests that measures memory function and other cognitive abilities. 
This test is easily reproducible and lasts between 45 and 75 minutes.  
Further inclusion criteria were the diagnosis of “questionable demented” (score=0.5) 
according to the CDR. Depressive symptoms were rated using the GDS with a score > 6 as 
cut off to discriminate patients with depression. All patients underwent CT scan or MRI of 
the brain to assess the presence and degree of  cerebral atrophy and causes of secondary 
dementia.  
Patients with aMCI showed a lower score in the ability of olfactory identification and 
discrimination worse than 18 months from first visit. The percentages of normosmic, 
hyposmic, anosmic patients at T0 and T1 based on the mean TDI score are reported in Table 
5. We demonstrated that all patients (100%)  who developed AD  were hyposmic at T0 while 
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of 20 patients who didn’t develop AD 12 (60%) were hyposmic and 1 (5%) was anosmic 
based on TDI score.  
 
aMCI patients T0 T1 
9 with AD, n (%) 
Score on TDI 
 
9 hyposmic (100%) 
 
9 hyposmic (100%) 
20 without AD, n 
(%) 
Score on TDI 
7 normosmic (35%) 
12 hyposmic (60%) 
1 anosmic (5%) 
5 normosmic (25%) 
14 hyposmic (70%) 
1 anosmic (5%) 
Table 5. Percentages of normosmic, hyposmic, anosmic patients at T0 and T1 based on the 
mean TDI score 
The correlation between individual neuropsychological tests of the MDB and the 3 olfactory 
functions (threshold-discrimination-identification) evalueted with the SSET  was examined 
with the Spearman correlation.  
The most statistically significant correlations were found between olfactory discrimination 
and copying designs with elements of programming, between olfactory discrimination and 
verbal fluency, between olfactory discrimination and immediate recall of Rey's 15 words 
and between olfactory identification and delayed recall of Rey's 15 words.  
The olfactory test has been shown to be sensitive and in some cases statistically more 
reliable of neuropsychological tests such as the MMSE. Another fact that emerges from the 
results of our study is that the olfactory test appears to allow a prediction of conversion to 
AD in aMCI who show a worsening of 'olfactory identification at follow-up. 9 of 29 patients 
with aMCI (31%) developed AD, and all had a worse olfactory deficit to 18 months from the 
first survey showing also unawareness of their olfactory deficit.  
This finding confirms the results of Devanand stating that the olfactory deficit associated 
with unawareness increase the risk of progression to AD.  
Our data show an early olfactory deficit in aMCI patients and suggest to introduce the study 
of the smell in early evaluation of aMCI patients. At follow-up we evidenced a  more rapid 
cognitive than olfactory decline but they must be confirmed on the basis of further studies 
on a larger sample population. We also demonstrated a significant progression from 
hyposmia to anosmia in aMCI patients which have developed AD after 18 months. This 
suggested the validity of the olfactory test as a possible early diagnostic marker of AD. 
Moreover we found in the 20 aMCI patients that did not developed AD an increase of the 
mean MMSE score at the 18 months follow-up. These findings is in concordance with 
epidemiological studies which suggest that the progression of MCI is heterogeneous and 
may be reversible, stable or progress to AD (Ritchie K et al., 2001; De Carli C., 2003). Förster 
et al. have instead shown in patients with early AD studied with SSET and FDG-PET a 
correlation between the scores in the identification, discrimination and olfactory threshold 
and different areas of brain activation (Förster et al., 2010). In our studies we confirmed the 
accuracy of the olfactory test to find an impairment of the olfactory identification function in 
the early stages of AD.  
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3. Conclusion 
The olfactory tests are a useful and reliable diagnostic aid for the identification of olfactory 
deficit. They are easy to use, with a low cost, they don’t take too much time for the 
administration and they are not influenced by the level of education. The ideal test should 
overcome the problem of the different ethnic and currently the most widely used 
standardized tests in clinical practice and research are the UPSIT and the SS. For a first rapid 
evaluation the screening identification test can be used but in case of abnormal results or if 
cognitive disorders are suspected a complete test is strongly reccomended. 
The only olfactory test is obviously not sufficient for the early diagnosis of AD but its high 
sensitivity is now accepted and should be included into a full battery of neuropsychological 
tests and other diagnostic aids (ApoE, PET or SPECT brain, functional MRI, etc..) commonly 
used to evaluate these patients.  
The role of the ENT specialist  in this area  is very important as fundamental to ensuring the 
reliability of the olfactory test excluding with a careful selection of patients hyposmia 
secondary to malformations, acute and chronic inflammatory phenomena, allergy, exposure 
to irritants. We also recommend to avoid the self-administration expecially if the test is not 
for screening aims but is part of the clinical routine for diagnosis.  
In conclusion, we can assert that the role of olfactory deficit in neurodegenerative diseases is 
still underestimated, mainly for the problem of an early and correct identification of a 
clinical disorder. Long-term studies can determine the real predictive value of hyposmia in 
AD and the efficacy of early treatment even on olfactory function.  
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